Hearing loss affects over 1.5 billion people globally. In adults over 60, roughly one in three lives with it. Until now, there has been no drug that prevents it. A new study from Harvard Medical School and Massachusetts Eye and Ear may change that.
The Discovery
Researchers identified a specific inflammatory pathway — mediated by Janus kinase (JAK) proteins — that progressively damages cochlear hair cells as we age. In mice, when this pathway was blocked using a JAK inhibitor (a class of drug already approved for rheumatoid arthritis and skin conditions), cochlear inflammatory damage was substantially reduced.
Treated mice maintained significantly better hearing thresholds than untreated controls. Their auditory brainstem responses remained close to youthful baselines. They could hear clearly at frequencies and volumes that their untreated littermates could not.
Why This Is Significant
JAK inhibitors' safety profiles are already well established through clinical use. The path to clinical trials is therefore shorter than for a novel, untested compound. And the finding confirms that age-related hearing loss has a druggable inflammatory mechanism — not simply inevitable wear and tear.
"We've long thought of presbycusis as just wear and tear," said one lead researcher. "What this shows is that there's an active destructive process we may be able to stop."
Age-related hearing loss is also associated with significantly increased risk of cognitive decline, depression, and dementia. A pill that keeps the cochlea healthy could have downstream health effects far beyond auditory function — for the billions of people who have simply accepted that getting older means hearing less.
Sources: Massachusetts Eye and Ear / Harvard Medical School, 2026; Journal of Experimental Medicine; ASHA; WHO Global Hearing Report
